Sugi Predict

Sugi Predict / Compounds / SCHEMBL699222

SCHEMBL699222

SCHEMBL699222

O=[N+]([O-])c1ccc2[nH]c3c(c2c1)CCCC3

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 8/20 1.00
▸ MEN1 O00255 4/20 1.00
▸ KMT2A Q03164 4/20 1.00
▸ SMN1; SMN2 Q16637 2/20 1.00
▸ GFER P55789 1/20 1.00
▸ LMNA P02545 4/20 0.60
▸ ALDH1A1 P00352 2/20 0.60
▸ TDP1 Q9NUW8 2/20 0.59
▸ BAZ2B Q9UIF8 1/20 0.58
▸ NPSR1 Q6W5P4 1/20 0.56
▸ HTT P42858 1/20 0.56
▸ NCOA1 Q15788 1/20 0.56
▸ NCOA3 Q9Y6Q9 1/20 0.56
▸ CA12 O43570 1/20 0.51
▸ CA9 Q16790 1/20 0.51
▸ F2 P00734 1/20 0.50
▸ KDM4E B2RXH2 1/20 0.50
▸ CTSV O60911 1/20 0.49
▸ CTSL P07711 1/20 0.49
▸ PARP1 P09874 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31233605 1.00 MAPT (1.00) MAPTMEN1KMT2ASMN1; SMN2GFER
SCHEMBL10735632 0.98 MAPT (0.97) MAPTMEN1KMT2ASMN1; SMN2GFER
SCHEMBL16140437 0.88 MAPT (0.78) MAPTMEN1KMT2ASMN1; SMN2GFER
SCHEMBL10740063 0.87 MAPT (0.76) MAPTMEN1KMT2ASMN1; SMN2GFER
SCHEMBL31154620 0.84 MAPT (0.72) MAPTMEN1KMT2ASMN1; SMN2GFER
SCHEMBL13328947 0.81 MAPT (0.68) MAPTMEN1KMT2ASMN1; SMN2GFER
SCHEMBL30359276 0.81 MAPT (0.68) MAPTMEN1KMT2ASMN1; SMN2GFER
SCHEMBL4162219 0.78 MAPT (0.69) MAPTMEN1KMT2ASMN1; SMN2GFER
SCHEMBL13328971 0.78 BAZ2B (0.71) MAPTMEN1KMT2ASMN1; SMN2GFER
SCHEMBL3877880 0.78 MAPT (0.64) MAPTMEN1KMT2ASMN1; SMN2GFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250243344-A1 COMPOUND, RUBBER BLEND CONTAINING THE COMPOUND, VEHICLE TIRE COMPRISING THE RUBBER BLEND IN AT LEAST ONE COMPONENT, PROCESS FOR PREPARING THE COMPOUND, AND USE OF THE COMPOUND AS AN ANTI-AGING AGENT AND/OR ANTIOXIDANT CONTINENTAL REIFEN DEUTSCHLAND GMBH (DE) 2025-07-31 — — US disclosed
US-RE50453-E1 Indole derivatives as CFTR modulators VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-06-10 — — US disclosed
US-20240092766-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMA (US) 2024-03-21 — — US disclosed
WO-2023198253-A1 COMPOUND, RUBBER BLEND CONTAINING THE COMPOUND, VEHICLE TIRE COMPRISING THE RUBBER BLEND IN AT LEAST ONE COMPONENT, PROCESS FOR PREPARING THE COMPOUND, AND USE OF THE COMPOUND AS AN ANTI-AGING AGENT AND/OR ANTIOXIDANT CONTINENTAL REIFEN DEUTSCHLAND GMBH (DE) 2023-10-19 — — WO disclosed
US-11639347-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-05-02 — — US disclosed
US-11639347-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-05-02 — — US disclosed
US-20230127655-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-04-27 — — US disclosed
US-20230127655-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-04-27 — — US disclosed
US-20230100634-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-03-30 — — US disclosed
US-20220411410-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED 2022-12-29 — — US disclosed
US-7534897-B2 Indole arylsulfonaimide compounds exhibiting PGD 2 receptor antagonism SHIONOGI & CO., LTD. (JP) 2009-05-19 — — US disclosed
WO-2007117715-A2 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-18 — — WO disclosed
US-20070244159-A1 including Cystic Fibrosis Transmembrane Conductance Regulator (\"CFTR\"), such as 1-(Benzo[d][1,3]dioxol-5-yl)-N-(2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide, used for the treatment of genetic disorders such as cystic fibrosis, emphysema, hemochromatosis and protein C deficiency VERTEX PHARMACEUTICALS INCORPORATED 2007-10-18 — — US disclosed
US-20070244159-A1 including Cystic Fibrosis Transmembrane Conductance Regulator (\"CFTR\"), such as 1-(Benzo[d][1,3]dioxol-5-yl)-N-(2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide, used for the treatment of genetic disorders such as cystic fibrosis, emphysema, hemochromatosis and protein C deficiency VERTEX PHARMACEUTICALS INCORPORATED 2007-10-18 — — US disclosed
US-20070244159-A1 including Cystic Fibrosis Transmembrane Conductance Regulator (\"CFTR\"), such as 1-(Benzo[d][1,3]dioxol-5-yl)-N-(2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide, used for the treatment of genetic disorders such as cystic fibrosis, emphysema, hemochromatosis and protein C deficiency VERTEX PHARMACEUTICALS INCORPORATED 2007-10-18 — — US disclosed
US-20050171143-A1 Compound exhibiting pgd 2 receptor antagonism SHIONOGI & CO., LTD. (JP) 2005-08-04 — — US disclosed
EP-1505061-A1 COMPOUND EXHIBITING PGD 2 RECEPTOR ANTAGONISM SHIONOGI & CO., LTD. (JP) 2005-02-09 — — EP disclosed
US-6713473-B1 6-CARBAMATE-1,2,3,4-TETRAHYDROCARBAZOLE DERIVATIVES; AFFINITY FOR NEUROPEPTIDE Y RECEPTORS MEIJI SEIKA KAISHA, LTD. (JP) 2004-03-30 — — US disclosed
EP-1184373-A1 TRICYCLIC COMPOUNDS MEIJI SEIKA KAISHA LTD. (JP) 2002-03-06 — — EP disclosed
US-4118561-A ANTIBACTERIAL, SYNERGISTIC, ANTI-CANCER ACTIVITY, ANTI-FOLIC ACID ACTIVITY AMERICAN HOME PRODUCTS CORPORATION (US) 1978-10-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220411410-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS CFTR, ABCB1, ABCC2 MAPT 4484/4885MEN1 4687/4885KMT2A 4313/4885
US-20240092766-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS CFTR, ABCB1, ABCC2 MAPT 4484/4885MEN1 4687/4885KMT2A 4313/4885
US-20050171143-A1 Compound exhibiting pgd 2 receptor antagonism CYSLTR2, CYSLTR1, HRH2 MAPT 4770/4885MEN1 4737/4885KMT2A 2134/4885
US-11639347-B2 Modulators of ATP-binding cassette transporters CFTR, ABCB1, ABCC2 MAPT 4484/4885MEN1 4687/4885KMT2A 4313/4885
US-20230100634-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS CFTR, ABCB1, ABCC2 MAPT 4484/4885MEN1 4687/4885KMT2A 4313/4885
US-20230127655-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS CFTR, ABCB1, ABCC2 MAPT 4484/4885MEN1 4687/4885KMT2A 4313/4885
US-20070244159-A1 including Cystic Fibrosis Transmembrane Conductance Regulator (\"CFTR\"), such as 1-(Benzo[d][1,3]dioxol-5-yl)-N-(2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide, used for the treatment of genetic disorders such as cystic fibrosis, emphysema, hemochromatosis and protein C deficiency CFTR, ABCD3, ABCC2 MAPT 4784/4885MEN1 4579/4885KMT2A 3350/4885
US-20250243344-A1 COMPOUND, RUBBER BLEND CONTAINING THE COMPOUND, VEHICLE TIRE COMPRISING THE RUBBER BLEND IN AT LEAST ONE COMPONENT, PROCESS FOR PREPARING THE COMPOUND, AND USE OF THE COMPOUND AS AN ANTI-AGING AGENT AND/OR ANTIOXIDANT POT1, TERT, CCNE2 MAPT 2273/4885MEN1 3655/4885KMT2A 3840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.